Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc.

LRMR·NASDAQ

$3.20

-3.0%
HealthcareBiotechnology

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$273.97M
EPS-2.2700
P/E Ratio-1.41
Earnings Date08/06/2026

lrmr

Cost of Revenue

Last Annual Value

350.00K

3-Year CAGR

%

5-Year CAGR

18%

10-Year CAGR

17%

Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. Competitors Analysis of Cost of Revenue

LRMR · NASDAQ
CompanyCost of Revenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
350.00K
N/AN/A5.1% 
ALEC logo
Alector, Inc.
NASDAQ:ALEC
9.66M
3.0%-44.9%-3.4%
0.00
N/AN/AN/A
0.00
N/AN/AN/A
11.54M
N/AN/AN/A
8.44M
-1.0%16.0%N/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
1.80M
1.8%N/AN/A
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
4.28M
N/A2.2%N/A
0.00
N/AN/AN/A
Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. Fair Value Envelope

LRMR · NASDAQ

Our analysis suggests that LRMR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.2014, this represents a potential HIDDEN relative to our calculated worth for Larimar Therapeutics, Inc..

Intrinsic Value
Current Price: $3.2014